When was Cleave Therapeutics founded?

Cleave Therapeutics was founded in 2010 and raised its 1st funding round 1 year after it was founded.

Where is Cleave Therapeutics located?

Cleave Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California.

Is Cleave Therapeutics a funded company?

Cleave Therapeutics is a funded company, having raised a total of $103M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 11, 2011.

How much is Cleave Therapeutics worth?

The latest valuation of Cleave Therapeutics is $***** as of Apr 09, 2013.

When was the latest funding round of Cleave Therapeutics?

Cleave Therapeutics' latest funding was a $***** Series B round on Aug 06, 2019, with participation from 7 investors. Its primary sector is Oncology. In United States, the Oncology sector has seen $2.85B in funding in 2026 to date.

Where does Cleave Therapeutics rank among its competitors?

Cleave Therapeutics ranks 743rd amongst 3681 active competitors, of which 1255 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Cleave Therapeutics?

Cleave Therapeutics' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Cleave Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Cleave Therapeutics is a series B company based in San Francisco (United States), founded in 2010 by Raymond Deshaies, Francesco Parlati and Seth Cohen. It operates as a Developer of VCP/p97 inhibitors for oncology and neurodegenerative diseases. Cleave Therapeutics has raised $103M in funding from investors like Orbimed, USVP and 5AM Ventures, with a current valuation of $*****. The company has 3681 active competitors, including 1255 funded and 848 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Developer of VCP/p97 inhibitors for oncology and neurodegenerative diseases. The company focuses on valosin-containing protein (VCP)/p97 is involved in protein homeostasis and cellular stress pathways and is targeted for the treatment of cancer and neurodegenerative diseases. The lead candidate is CB-5339, an oral second-generation inhibitor for acute myeloid leukemia (AML).

Website: cleavetherapeutics.com
Social
Registered Address: San Francisco, California

Key Metrics

Founded Year

2010

Location

San Francisco, United States

Stage

Series B

Total Funding

$103M in 4 rounds

Latest Funding Round

Series B, Aug 06, 2019, $*****

Post Money Valuation

$***** as on Apr 09, 2013

Investors

Orbimed & 11 more

Ranked

743^rd among 3681 active competitors

Similar Companies

Jazz Pharmaceuticals & 3505 more

View Cleave Therapeutics' full profile

Cleave Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CLEAVE THERAPEUTICS, INC. CIN: 274994421 , United States, Active	Dec 31, 1999	-	4 (As on Dec 31, 2022)	-
Cleave Therapeutics, Inc CIN: 27-4994421 , United States, Active	Jun 09, 2010	-	18 (As on Dec 31, 2021)	-

Cleave Therapeutics has raised a total funding of $103M over 4 rounds. Its first funding round was on Oct 11, 2011. Its latest funding round was a Series B round on Aug 06, 2019 for $*****. 7 investors participated in its latest round. Cleave Therapeutics has 12 institutional investors.

Here is the list of recent funding rounds of Cleave Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 06, 2019	8416245	Series B	8147970	7797365	1230221	1569836
Aug 08, 2016	7900945	Series B	5333851	2636263	1813215	9648959
Apr 09, 2013	5414082	Series A	1161307	7061229	New Enterprise Associates	1547471

Access funding benchmarks and valuations. Sign up today!

View details of Cleave Therapeutics's funding rounds and investors

The founders of Cleave Therapeutics are Raymond Deshaies, Francesco Parlati and Seth Cohen.

Here are the details of Cleave Therapeutics' key team members:

Raymond Deshaies: Co-Founder of Cleave Therapeutics.
Francesco Parlati: Former Co-Founder of Cleave Therapeutics.
Seth Cohen: Co-Founder of Cleave Therapeutics.

View details of Cleave Therapeutics's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cleave Therapeutics include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Cleave Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, F-Prime Capital & 23 others	71/100
743rd	Cleave Therapeutics 2010, San Francisco (United States), Series B	Developer of VCP/p97 inhibitors for oncology and neurodegenerative diseases	$103M	Celgene, Nextech Invest & 10 others	48/100